Search
Abaloparatide
go.drugbank.com/drugs/DB05084ApprovedInvestigational[L740] It is a synthetic 34 amino acid peptide with 41% homology to human parathyroid hormone 1-34 and human PTHrP 1-34. … [L740] It was first approved by the FDA on April 28, 2017,[A256748] for the treatment of osteoporosis in postmenopausal women and is also used to increase bone density in men with osteoporosis.
Fluoroestradiol F-18
go.drugbank.com/drugs/DB15690ApprovedInvestigationalacross metastases (i.e. to identify sites that no longer express ER) without the need for multiple biopsies. … [L14096] The ability to image ER-positive tumors _in vivo_ is advantageous in that, while helping to visualize tumor progression/regression, it may also be used to assess for heterogeneity in ER expression
Hyoscyamine
go.drugbank.com/drugs/DB00424ApprovedInvestigational[A228423] Research into the action of hyoscyamine in published literature dates back to 1826. … [A228713] Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimuscarinic properties.
Alaproclate
go.drugbank.com/drugs/DB13233ExperimentalAlaproclate was developed as one of the first selective serotonin reuptake inhibitor (SSRI) antidepressants by Astra AB (now AstraZeneca) in the 1970s. … Alaproclate has also been found to act as a non-competitive NMDA receptor antagonist although without discriminative stimulus properties similar to phencyclidine.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeOMS-103HP
go.drugbank.com/drugs/DB05303InvestigationalOMS103HP is the first drug being developed to improve joint function following arthroscopic surgery, one of the most common procedures performed today by orthopedic surgeons.
Midomafetamine
go.drugbank.com/drugs/DB01454IllicitInvestigationalIt is commonly referred to as MDMA or ecstasy. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSuccinylcholine
go.drugbank.com/drugs/DB00202ApprovedInvestigationalSuccinylcholine is a depolarizing skeletal muscle relaxant consisting of two molecules of the endogenous neurotransmitter [acetylcholine] (ACh) linked by their acetyl groups. … Its rapid onset and offset, with effects beginning within 60 seconds of intravenous administration and lasting between four to six minutes, make succinylcholine particularly useful in the setting of short
Bebtelovimab
go.drugbank.com/drugs/DB16755ApprovedWithdrawn[L43827] On November 30, 2022, the EUA for bebtelovimab was officially withdrawn due to a lack of efficacy against Omicron subvariants, therefore bebtelovimab is no longer authorized for emergency use … [L40328] Bebtelovimab was issued an emergency use authorization (EUA) by the FDA on February 11, 2022, for the treatment of mild-to-moderate COVID-19 in select patients.
Inosinic Acid
go.drugbank.com/drugs/DB04566InvestigationalA purine nucleotide which has hypoxanthine as the base and one phosphate group esterified to the sugar moiety.
Orphenadrine
go.drugbank.com/drugs/DB01173ApprovedInvestigationalA muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.
Synonyms: o-methyldiphenhydramine, o-monomethyldiphenhydramineMixtures: MYOGESIC-O